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ABSTRACT
Polycystic ovary syndrome (PCOS) is the most common cause of
anovulation in women. Previous studies suggest that the pathogen-
esis of PCOS may involve interrelated abnormalities of the insulin-
like growth factor (IGF) and ovarian steroidogenesis systems. We
investigated this hypothesis in fasting serum samples from 140
women with PCOS (age, 27.4 6 0.4 yr; body mass index, 26.3 6 0.5
kg/m2; mean 6 SEM). IGF-related parameters were also studied in a
group of normoovulatory women (n 5 26; age, 26 6 4 yr; body mass
index, 23.6 6 4.3 kg/m2). For the PCOS group, the mean testosterone
(T) level was 2.5 6 0.1 nmol/L, and it was significantly correlated with
LH (r 5 0.41; P , 1026), estrone (r 5 0.33; P 5 0.016), estradiol (r 5
0.18; P 5 0.04), and androstenedione (AD; P , 1026), but not with
dehydroepiandrosterone sulfate (P 5 0.71), a marker of adrenal ste-
roidogenesis. T and AD were also related to total ovarian follicle
number and ovarian size, as previously found with normoovulatory
women (1). There were no differences between the PCOS subjects and
the normoovulatory group for total IGF-I, IGF-II, or IGF-binding
protein-3 (IGFBP-3). However, IGFBP-1 levels were significantly de-
creased in the PCOS group (1.0 6 0.2 vs. 7.3 6 1.1 ng/mL; P , 0.001)
and were inversely correlated with serum insulin levels (r 5 20.50;
P , 1028). Serum levels of free IGF-I (fIGF-I) were elevated (5.9 6 0.3
vs. 2.7 6 0.3 ng/mL; P , 0.001) in inverse relation with IGFBP-1 (r 5
20.31; P 5 0.046). Serum fIGF-I levels were related to total follicle
number (r 5 20.35; P , 1024) and to the ratio of sex hormone-binding
globulin to T (r 5 20.23; P 5 0.009). However, these relationships
were not independent of other variables. Despite the more than 2-fold
elevation in fIGF-I levels, significant relationships between fIGF-I
and markers of ovarian steroidogenesis (T, AD, estradiol, and estrone)
could not be demonstrated.
In conclusion, although we confirmed correlations between LH and
hyperandrogenemia and have found abnormalities in the IGF system
in a large cohort of PCOS subjects, a direct relationship between
hyperandrogenism and the IGF system could not be shown. Previous
studies suggest that elevated LH and hyperinsulinemia lead to excess
ovarian androgen synthesis in PCOS and that the intraovarian IGF
system is important for normal follicle development and may be im-
portant in the arrested state of follicle development in PCOS. How-
ever, the data presented in this cross-sectional study suggest that
insulin-related changes in circulating IGFBP-1 and subsequent ele-
vation of fIGF-I reflect insulin resistance and have little enhancing
effects on ovarian steroidogenesis in this disorder. (J Clin Endocrinol
Metab 84: 3030–3035, 1999)
POLYCYSTIC ovary syndrome (PCOS) is characterizedby oligo- or anovulation, oligo- or amenorrhea, and
hyperandrogenism (1, 2). Insulin resistance and obesity are
also common features of the syndrome (3). Within the poly-
cystic ovary, the early stages of folliculogenesis occur, al-
though selection of a dominant, preovulatory follicle does
not occur, leading to accumulation of small antral follicles (4).
Normal ovarian cyclicity is regulated by gonadotropins and
intraovarian growth factor systems, and abnormalities in
these systems are postulated to play roles in the pathogenesis
of follicle maturation arrest in PCOS (5). In vitro androgen
synthesis is stimulated by both insulin-like growth factor I
(IGF-I) and insulin acting on thecal-interstitial cells (6–8). It
has been postulated that elevated insulin and IGF-I along
with elevated LH, acting on the thecal compartment in vivo,
contribute to the hyperandrogenemia observed clinically in
PCOS (2, 3, 5, 9, 10).
The in vivo actions of IGF-I are modulated by a system
of circulating binding proteins (IGFBPs). Six structurally
homologous, but functionally distinct, IGFBPs have been
characterized and are numbered according to the sequence
of their identification. Of the six IGFBPs, IGFBP-1 has a
unique role in the dynamic regulation of serum IGF-I
bioavailability (11–14). In serum, IGFBP-1 has been found
to correlate inversely with estimates of the free fraction of
IGF-I (12, 14), a relationship that has not been reported for
the other IGFBPs.
Serum and follicular fluid IGFBP-1 concentrations are de-
creased in PCOS, presumably due to hyperinsulinism and
consequent suppression of IGFBP-1 synthesis (5, 14–16). Al-
though the levels of total serum IGF-I are normal in PCOS
(17, 18), the decreased IGFBP-1 concentrations could lead to
elevated levels of free IGF-I (fIGF-I), which may then stim-
ulate ovarian androgen synthesis. A limited study in which
serum fIGF-I levels were determined after a Sep-Pak extrac-
tion procedure found elevated levels of fIGF-I compared to
control values (18). Herein we report more extensive inves-
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tigation of fIGF-I and other components of the IGF system in
PCOS in relation to hormonal parameters.
Materials and Methods
Subjects and protocol
The involvement of human subjects in this study was approved by
the ethical committee of Dijkzigt Academic Hospital and Erasmus Uni-
versity Medical School. Signed informed consent was obtained from
each subject before enrollment in the study. Subjects with PCOS [n 5 140;
age, 27.4 6 0.4 yr; body mass index (BMI), 26.3 6 0.5 kg/m2; mean 6
sem] were recruited from the clinic population at Dijkzigt Academic
Hospital. PCOS was defined as anovulatory infertility, normal serum
FSH (1.0–10.0 IU/L) levels, and at least two of the following criteria: 1)
obesity (BMI, .26 kg/m2), 2) hirsutism (Ferriman and Gallway score,
.8) (19), 3) elevated serum androgen levels [testosterone (T), .2
nmol/L; and/or androstenedione (AD), .15 nmol/L; and/or dehydro-
epiandrosterone sulfate (DHEAS), .10 mmol/L), 4) LH to FSH ratio
above 2, and 5) polycystic ovaries identified by transvaginal ultrasound
examination (20). Subjects were all oligo- or amenorrheic. Subjects taking
medications that might interfere with the study results or with clinically
significant thyroid disorder or hyperprolactinemia were excluded.
Blood samples were obtained after an overnight fast at the intake visit.
Transvaginal ultrasound examinations were also performed at that time
(20).
For comparisons of IGF-related measurements, samples were also
obtained from 26 healthy, normoovulatory women (age, 26 6 4 yr; cycle
length, 28 6 2 days; BMI, 23.6 6 4.3 kg/m2) (21). Subjects in this group
were recruited by advertisement, had no evidence of endocrine disorder,
and had been medicationfree for at least 3 months before the study.
Nonfasting blood samples were obtained during the follicular phase
(before day 13) of the menstrual cycle.
Assays
Blood was collected into glass tubes and centrifuged within 30 min
of collection, and the serum was removed and stored at 220 C until
assay. LH and FSH were determined by immunoradiometric assay
(IRMA; Medgenix, Fleurus, Belgium). AD, DHEAS, estradiol (E2), and
sex hormone-binding globulin (SHBG) were measured by RIA (Diag-
nostic Products, Los Angeles, CA), as previously described (22). Insulin
was measured by RIA (Diagnostic Systems Laboratories, Inc., Webster,
TX). Serum T was measured by RIA as previously described (23). Intra-
and interassay coefficients of variation (CVs) were, respectively, less
than 5% and less than 15% for LH, less than 3% and less than 8% for FSH,
less than 7% and less than 15% for AD, less than 4% and less than 6%
for DHEAS, less than 5% and less than 8% for E2, 4% and 5% for SHBG,
11% and 8% for insulin, and less than 3% and less than 5% for T. Other
assays and their inter- and intraassay CVs included: cortisol (Diagnostic
Products), 6.1% and 9.5%; 17-hydroxyprogesterone (24), 7% and 10%;
and estrone (E1; Diagnostic Systems Laboratories, Inc.), 6.5% and 9.1%.
Serum IGF-I and IGF-II were measured by IRMA after acid-ethanol
extraction (Diagnostic Systems Laboratories, Inc.). Intra- and interassay
CVs were 3% and 4% for IGF-I and 5% and 8% for IGF-II, with sensi-
tivities of 27 and 72 pg/mL, respectively. We previously reported char-
acteristics of these commercial assays and comparisons of the acid-
ethanol extraction procedure to acid chromatography (25). Free IGF-I
(fIGF-I) was measured by IRMA (Diagnostic Systems Laboratories, Inc.)
using the direct method (26). In brief, unaltered serum was incubated in
tubes that were precoated with anti-IGF-I antibody and washed, and the
bound analyte was detected using a radiolabeled anti-IGF-I antibody
directed to a second epitope. Intra- and interassay CVs were 5% and 8%,
respectively, with a sensitivity of 0.03 ng/mL.
IGFBP-1 and IGFBP-3 were measured by IRMA (Diagnostic Systems
Laboratories, Inc.). Intra- and interassay CVs were 5% and 5% for
IGFBP-1 and 1% and 2% for IGFBP-3, with sensitivities of 39 pg/mL and
0.5 ng/mL, respectively. Due to loss of standard curve linearity below
the last standard, the lower limit for the IGFBP-1 assay was set at the
level of the lowest standard (0.1 ng/mL) rather than at the minimal
detection limit.
Data analysis
Data were analyzed using Statmost software (Datamost Corp., Salt
Lake City, UT). Descriptive data are presented as the mean and sd unless
otherwise indicated. Comparisons between the PCOS and normoovu-
latory groups were analyzed using the Mann-Whitney rank sum test
(two-tailed P value). Correlations were made using the Spearman
method. Significance was defined as P , 0.05. Single and multiple linear
regressions were performed for selected data, with statistical signifi-
cance defined as P , 0.05.
Results
The PCOS group had 31 6 2 follicles in both ovaries on
ultrasound examination, with right and left ovarian volumes
of 12.4 6 0.5 and 11.1 6 0.5 mL, respectively, and a total
ovarian volume of 23.5 6 0.9 mL. As shown in Table 1, mean
serum gonadotropin and sex steroid levels for the PCOS
subjects were within the expected ranges. However, mean
LH and androgen (T, DHEAS, and AD) were near the upper
end of their respective normal ranges. T was correlated with
LH (r 5 0.41; P , 1026; n 5 138), but not significantly with
FSH (r 5 0.17; P 5 0.052; n 5 138). T was also related to AD
(r 5 0.41; P , 1026; n 5 136), E2 (r 5 0.18; P 5 0.04; n 5 137),
and E1 (r 5 0.33; P 5 0.016), but not to DHEAS (r 5 0.03; P 5
0.71; n 5 136). Total ovarian volume was significantly cor-
related with AD (r 5 0.17; P 5 0.05; n 5 131) and total follicle
number (r 5 0.63; P , 10215; n 5 0.63) and tended to vary
with T (r 5 0.16; P 5 0.06; n 5 133) and days since the last
menstrual period (r 5 0.22; P 5 0.06; n 5 72). Total follicle
number was related to T (r 5 0.23; P 5 0.008; n 5 134), as also
found in normoovulatory women (1), and was correlated
with insulin (r 5 0.058; P 5 0.010). Total ovarian volume,
however, was not correlated with insulin (r 5 0.005; P 5
0.46).
Total IGF-I, IGF-II, and IGFBP-3 were not different be-
TABLE 1. Results summary for the PCOS subjects
Analyte n Mean SEM Median Range Normal range
FSH (mIU/L) 139 4.2 0.1 4.2 0.2–9.3 1–10a
LH (mIU/L) 139 7.9 0.4 7.7 0.8–35.5 1–8a
E1 (pmol/L) 54 386 18 378 170–777 138–510
E2 (pmol/L) 138 244 14 204 10–1000 70–200
T (nmol/L) 139 2.5 0.1 2.3 0.6–5.6 0.5–3.0
T/SHBG 132 0.079 0.006 7.2 0.004–0.39 ,4.5
DHEAS (nmol/L) 136 8.5 0.4 8.2 1.6–23.8 1.2–10.0
AD (nmol/L) 137 15.5 0.6 14.6 6.1–56.9 2–15
SHBG (nmol/L) 133 49 3 40 6–183 20–120
See text for explanation of abbreviations.
a Normal ranges for FSH, LH, E2, and E1 are given for the follicular phase of the menstrual cycle.
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tween the PCOS and normoovulatory groups (Table 2). In-
sulin concentrations tended to be higher in the fasting PCOS
group than in the nonfasting controls. However, this did not
reach statistical significance. Within the PCOS group,
IGFBP-3 was strongly correlated with insulin (r 5 0.34;
P 5 0.004; n 5 108), IGF-I (r 5 0.42; P , 1026; n 5 124), IGF-II
(r 5 0.55; P , 1029; n 5 116), and total IGF (IGF-I and IGF-II;
r 5 0.60; P , 10212; n 5 116). Insulin was inversely related
to IGFBP-1 (r 5 20.50; P , 1028; n 5 119; Fig. 1) and SHBG
(r 5 20.33; P 5 0.0004; n 5 114) and correlated to BMI
(r 5 0.49; P , 1027; n 5 114). IGFBP-1 was correlated to SHBG
(r 5 0.35; P , 1024; n 5 133) and inversely related to BMI (r 5
20.61; P , 10213; n 5 131). The PCOS group had lower
IGFBP-1 and significantly higher fIGF-I levels compared to
the normoovulatory subjects (Table 2). Moreover, 69 of 140
(49%) IGFBP-1 measurements in this group were at or below
the low standard for the assay (0.1 ng/mL) and were tabu-
lated at this level for data analysis; this had no effect on the
analyses involving IGFBP-1, except in the case of IGFBP-1 vs.
fIGF-I (see below).
The relationships of fIGF-I to other variables were exam-
ined in depth for the PCOS group. fIGF-I, but not IGF-I, was
correlated with SHBG (fIGF-I vs. SHBG: r 5 0.29; P 5 0.0007;
n 5 133; IGF-I vs. SHBG: r 5 20.11; P 5 0.19; n 5 133).
Although no overall relationships between fIGF-I and
IGFBP-1 were apparent (r 5 0.006; P 5 0.94; n 5 140), this
analysis was limited by the fact that 49% of IGFBP-1 mea-
surements were at or below the low standard in the assay
(Fig. 1). Subanalysis using only those data points with IGFBP
above 0.1 revealed a negative relationship between these
variables (r 5 20.31; P 5 0.046; n 5 71). fIGF-I tended to vary
with total IGF-I and inversely with IGF-II, but these rela-
tionships were not statistically significant (r 5 0.14; P 5 0.09;
n 5 140 and r 5 20.17; P 5 0.054; n 5 124, respectively).
fIGF-I was also negatively related to BMI (r 5 20.27; P 5
0.0018; n 5 131).
The relationships among fIGF-I, clinical parameters, and
gonadotropin and steroid levels were also examined. fIGF-I
varied inversely with total numbers of ovarian follicles ob-
served on ultrasound (r 5 20.35; P , 1024; n 5 135). Total
ovarian volume was inversely correlated with fIGF-I (r 5
20.23; P 5 0.007; n 5 134). fIGF-I also varied inversely with
DHEAS (r 5 20.19; P 5 0.03; n 5 136), but was unrelated to
LH, FSH, T, AD, or E2 .
The ratio of T to SHBG, an indicator of free T, was inversely
related to fIGF-I (r 5 20.23; P 5 0.009; n 5 132) and correlated
to BMI (r 5 0.50; P , 1028; n 5 123), total follicle number (r 5
0.32; P 5 0.0003; n 5 126), LH (r 5 0.20; P 5 0.02; n 5 131),
and FSH (r 5 0.19; P 5 0.03; n 5 131). This ratio was also
correlated to AD (r 5 0.26; P 5 0.002; n 5 129), DHEAS (r 5
0.23; P 5 0.01; n 5 129), and E1 (r 5 0.38; P 5 0.007; n 5 51)
and inversely related to progesterone (r 5 20.24; P 5 0.007;
n 5 129). Unlike fIGF-I, total IGF-I was not statistically re-
lated to any clinical or non-IGF biochemical measure. How-
ever, IGF-II was correlated to DHEAS (r 5 0.26; P 5 0.003;
n 5 122).
FIG. 1. Inverse relationship between insulin and IGFBP-1 (A) and
relationship between fIGF-I and IGFBP-1 (B; see text).
TABLE 2. Insulin, IGF family, and BMI results
Analyte
PCOS group Healthy, normo-ovulatory group P value
(2-tailed)n Mean SEM Median Range n Mean SEM Median Range
Insulina 119 14.3 1.8 7.2 0.2–115.4 26 10.0 2.8 4.0 0.2–62.0 0.14
IGF-I 140 265 8 258 107–612 26 296 17 300 145–537 0.08
IGF-II 124 476 8 480 283–740 26 480 13 480 347–592 0.46
fIGF-I 140 5.9 0.3 5.6 0.7–15.2 26 2.7 0.3 2.2 0.7–5.5 ,1026
IGFBP-1 140 1 0.2 0.2 0.1–10.7 26 7.3 1.1 7.8 0.1–20.0 ,1026
IGFBP-3 124 4030 70 4051 2210–6339 26 3982 101 3998 3084–5043 0.82
BMI (kg/m2) 140 26.3 0.48 25.9 16.7–40.2 26 23.6 0.83 22.8 18.5–37.6 0.38
a Fasting levels in the PCOS group; nonfasting levels in the normal ovulatory group.
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Discussion
Although PCOS is the most common pathological cause of
anovulation, the pathogenesis of this syndrome has not been
defined. Previous studies suggest that abnormalities of the
insulin and IGF systems, including hyperinsulinemia, low
IGFBP-1, and increased fIGF-I, may be involved (3, 5, 14). Our
current investigations were conducted to explore further this
hypothesis in a large PCOS cohort. As expected, according
to the definition of the syndrome, the characteristics of our
PCOS population are similar to those reported in other stud-
ies, including a history of anovulation and infertility, normal
FSH, hyperandrogenism, hirsutism, obesity, relatively ele-
vated LH levels, and polycystic ovaries. Hyperandrogenism
in PCOS has been attributed to the actions of LH and insulin
on ovarian steroidogenesis (27–30). In the current study LH
was more strongly correlated to T and AD than was FSH,
whereas DHEAS, a measure of adrenal steroidogenesis, was
not significantly related to gonadotropin levels. T and AD
were also variably related to ovarian size and follicle number
in PCOS subjects as well as in normoovulatory women (1).
Overall, the gonadotropin and steroid data are consistent
with LH stimulation of ovarian androgenesis in PCOS and
are consistent with theoretical models of ovarian steroido-
genesis (31, 32).
The observation that insulin and IGF-I stimulate ovarian
androgen production in vitro (7, 8, 33–35) coupled with the
occurrence of hyperinsulinemia, low serum IGFBP-1, and
increased serum fIGF-I in vivo have led to the hypothesis that
these peptide hormones may also be involved in the patho-
genesis of PCOS (7, 5, 17, 36). In addition, local production
of several components of the IGF system have been identified
in the ovary, where they are postulated to play roles in
normal and abnormal follicle development and atresia
(5.32.37–40). In the current study, serum insulin concentra-
tions were not significantly higher in the PCOS group. How-
ever, the comparative normoovulatory group samples were
obtained while subjects were nonfasting, whereas the PCOS
group samples were obtained during fasting. Therefore, it is
likely that the between-group differences were underesti-
mated. On the other hand, the fasting insulin concentrations
in PCOS reported here and in other studies (41) are not
consistently elevated, and average levels are well within
expected fasting ranges. Fasting insulin is not a particularly
good marker of insulin secretion as are area under the curve
measurements. Therefore, it is not surprising that the fasting
insulin levels are only rough indicators of hyperinsulinemia
(42). In vitro studies have demonstrated that insulin stimu-
lates thecal androgen production and is synergistic with LH
in this regard (34, 35). Overall, our data do not support an
independent association of ovarian volume with insulin, al-
though insulin as a stimulus of androgen production by the
PCOS ovarian thecal compartment in vivo is likely to be an
important part of the hyperandrogenemia observed in this
disorder.
Total IGF-I levels are not elevated in PCOS (17). However,
estimates of the free fraction of serum IGF-I are clearly ele-
vated, as shown in the current study and a previous one (18).
The fIGF-I assay used in our study probably reflects both the
true free fraction and a dissociable (exchangeable) fraction of
IGF-I that is associated with low mol wt IGFBPs, and mea-
sured levels are directly related to other estimates of true
fIGF-I (26, 43, 44). In addition, in non-PCOS populations, a
dynamic inverse correlation between fIGF-I and IGFBP-1 has
been demonstrated (45, 46). IGFBP-1, in turn, is regulated by
insulin suppression of IGFBP-1 gene transcription, and an
inverse relationship between fasting insulin and IGFBP-1 has
been demonstrated in this study and in previous studies in
PCOS and other populations (12, 14, 15, 48). This regulation
most likely occurs in the liver. The physiological relevance of
elevated insulin or free IGF-I with regard to ovarian IGFBP-1
regulation is uncertain in the setting of PCOS, as most
women with PCOS are anovulatory, and IGFBP-1 is pro-
duced exclusively in this tissue in the preovulatory, domi-
nant follicle and in the corpus luteum. As the role of IGFBP-1
in human ovary is likely to regulate IGF-II mitogenic, anti-
apoptotic, and metabolic effects in the ovary, changes in
circulating or follicular fluid IGFBP-1 in women undergoing
controlled ovarian hyperstimulation may have an effect on
these IGF-II-mediated events in the developing follicle. How-
ever, this awaits further investigation.
Although the analysis was limited by the extremely low
levels of IGFBP-1, our data indicate that IGFBP-1 and fIGF-I
are inversely related in PCOS, as they are in other clinical
situations (13, 49). The physiology of this relationship is
incompletely defined. Although IGF-I inhibits IGFBP-1 se-
cretion (50) and gene transcription (47) in vitro, the situation
in serum is likely to be more complex and dependent on
several factors, including the concentration of IGFBP-1,
which is also regulated by insulin, and the concentration of
total IGF-I.
Based on our data and the previous literature, a reasonable
model for the insulin/IGF system in PCOS involves hyper-
insulinemia and consequent suppression of IGFBP-1, result-
ing in elevated levels of fIGF-I. Although the observed in-
verse correlation of BMI with fIGF-I would tend to argue
against this hypothesis, this relationship is difficult to assess
in a cross-sectional study due to the considerations discussed
above and to the fact that obesity is not invariably associated
with hyperinsulinemia. Indeed, with multiple regression
analysis (BMI, dependent variable; fIGF-I and insulin, inde-
pendent variables), the relationship of BMI to fIGF-I is weak-
ened (r 5 20.31; P 5 0.03; n 5 114), whereas a positive
correlation is maintained for BMI and insulin (r 5 0.13; P ,
1027). Inclusion of IGFBP-1 (values .0.1 ng/mL only) as a
third independent variable retains the relationship between
BMI and insulin (r 5 0.31; P 5 0.0004; n 5 56), whereas fIGF-I
(P 5 0.25) and IGFBP-1 (P 5 0.49) are eliminated.
Having confirmed the elevated concentrations of fIGF-I in
PCOS, we then asked whether fIGF-I may be related to other
clinical or biochemical abnormalities. fIGF-I was related to
total follicle number, suggesting a possible role in folliculo-
genesis; however, total follicle number and fIGF-I were both
related to latency since the last evidence of menstrual bleed-
ing. Multiple regression analysis with total follicle number as
the dependent variable and fIGF-I and days since last bleed-
ing as independent variables demonstrates a strong depen-
dence on the latter (P 5 0.0002; n 5 71), whereas the rela-
tionship to fIGF-I (P 5 0.0021) is reversed [regression
equation: total follicle number 5 41–2.3 (fIGF-I) 1 0.20
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(days0]. This suggests that total follicle number may be pri-
marily related to the duration of anovulation, whereas the
effects of fIGF-I may be secondary to other undefined factors,
although insulin levels correlate with follicle number (51).
A relationship between fIGF-I and ovarian steroids was
not observed in our study, which may argue against the
hypothesis of a direct role of fIGF-I in ovarian androgen
synthesis and hyperandrogenemia in vivo. A recent study
(52) reporting that clomiphene citrate administration to
women with PCOS lowers IGF-I levels but does not result in
alterations in androgen levels supports these findings. In the
current study, fIGF-I was correlated to SHBG and, as a con-
sequence, was inversely related to the ratio of T to SHBG.
However, this relationship was also complex, as insulin is
known to suppress SHBG concentrations in parallel with its
actions on IGFBP-1 (53, 54), and differential regulation of
SHBG and total IGF-I has been reported in PCOS (55). Mul-
tiple regression analysis with SHBG as the dependent vari-
able and insulin and fIGF-I as independent variables re-
vealed the following equation: SHBG 5 45.4 1 2.0 (fIGF-I) 2
0.44 (insulin); the relationship with insulin was significant
(P 5 0.006), whereas that with fIGF-I was not (0.054). The
levels of total IGF-I and IGF-II were notable for their lack of
suggestive correlations with other variables. The relationship
of IGF-II and DHEAS may be consistent with the reported
role of IGF-II in adrenal steroidogenesis (56).
In conclusion, we have conducted a detailed investigation
in a large cohort of women with PCOS to explore the hy-
pothesis that the IGF system (in particular, fIGF-I) is involved
in the pathogenesis of this condition. We confirmed that
PCOS is associated with 1) increased LH and hyperandro-
genemia and 2) changes in the insulin-IGF system, resulting
in elevated serum fIGF-I. However, a conclusive relationship
between elevated fIGF-I and circulating androgen levels
could not be demonstrated, perhaps due to the limitation of
the cross-sectional study design. Given the clearly demon-
strated abnormalities in the IGF system and previous in vitro
data indicating IGF stimulation of ovarian androgen pro-
duction, prospective studies of the dynamic in vivo relation-
ships between these systems are warranted. In addition, the
possibility that elevated fIGF-I concentrations could have
pathophysiological actions independent of effects on ovarian
steroidogenesis merits further consideration.
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